Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018-Reference-Cited by-同舟云学术

Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018

Published:2020-03 Issue:3 Volume:124 Page:261-267
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Vokinger Kerstin N.,Muehlematter Urs Jakob

Funder

Krebsforschung Schweiz

Publisher

Elsevier BV

Subject

Health Policy

Reference41 articles.

1. Access to cancer precision medicines in Switzerland – a comparative analysis (US and EU) and policy implications;Vokinger;Public Health Genomics,2019

2. https://www.fda.gov/.

3. https://www.ema.europa.eu/en.

4. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs;Zeukeng;European Journal of Clinical Pharmacology,2018

5. http://www.spezialitaetenliste.ch.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis;Frontiers in Public Health;2024-06-05

2. Differences in time to patient access to innovative cancer medicines in six European countries;International Journal of Cancer;2023-10-20

3. Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition;PharmacoEconomics;2023-10-19

4. The cancer premium – explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional study;eClinicalMedicine;2023-07

5. Analysis of cancer drug prices: a narrative review of literature;Journal of Pharmaceutical Health Services Research;2022-08-09